Rituxan Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
Conditions: Large B-cell Lymphoma; B-cell Lymphoma Interventions: Drug: Magrolimab; Drug: Rituximab; Drug: CAR T leukapheresis; Drug: Radiation Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 3, 2023 Category: Research Source Type: clinical trials

Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
Condition: CNS Lymphoma Interventions: Drug: Orelabrutinib; Drug: Rituximab; Drug: Chemotherapy Sponsor: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 3, 2023 Category: Research Source Type: clinical trials

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Condition: Lymphoma, Large B-Cell, Diffuse Intervention: Drug: Selinexor combined with lenalidomide and rituximab Sponsor: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 28, 2023 Category: Research Source Type: clinical trials